Cell cycle-specific changes in hTERT promoter activity in normal and cancerous cells in adenoviral gene therapy: A promising implication of telomerase-dependent targeted cancer gene therapy

International Journal of Oncology

Volumn 29, Issue 3, 2006, Pages 681-688

  Murofushi, Yoshiteru ^a   Nagano, Satoshi ^a,c   Kamizono, Junichi ^a,c   Takahashi, Tomoyuki ^a,b   Fujiwara, Hisayoshi ^d   Komiya, Setsuro ^c   Matsuishi, Toyojiro ^a,b   Kosai, Ken Ichiro ^a,b  

^a KURUME UNIVERSITY   (Japan)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c KAGOSHIMA UNIVERSITY   (Japan)

^d GIFU UNIVERSITY   (Japan)

Author keywords

Adenovirus; Cancer gene therapy; Cancer specificity; hTERT; Promoter; Targeting cancer; Telomerase; Telomere

Indexed keywords

DNA BINDING PROTEIN; MESSENGER RNA; TELOMERASE;

ADENOVIRUS; ARTICLE; BONE TUMOR; CELL CULTURE; CELL CYCLE G0 PHASE; CELL CYCLE S PHASE; COLON TUMOR; ENZYME ACTIVE SITE; ENZYMOLOGY; GENE TARGETING; GENE THERAPY; GENE VECTOR; GENETICS; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; NEOPLASM; OSTEOSARCOMA; PROMOTER REGION;

ADENOVIRIDAE; BONE NEOPLASMS; CARCINOMA, HEPATOCELLULAR; CATALYTIC DOMAIN; COLONIC NEOPLASMS; DNA-BINDING PROTEINS; G0 PHASE; GENE TARGETING; GENE THERAPY; GENETIC VECTORS; HUMANS; LIVER NEOPLASMS; NEOPLASMS; OSTEOSARCOMA; PROMOTER REGIONS (GENETICS); RNA, MESSENGER; S PHASE; TELOMERASE; TUMOR CELLS, CULTURED;

EID: 33749345778     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.29.3.681     Document Type: Article

References (45)

1. Keith WN, Bilsland A, Evans TR and Glasspool RM: Telomerase-directed molecular therapeutics. Expert Rev Mol Med 2002: 1-25, 2002.
2. Liu L, Lai S, Andrews LG and Tollefsbol TO: Genetic and epigenetic modulation of telomerase activity in development and disease. Gene 340: 1-10, 2004. (Pubitemid 39360227)
3. Blackburn EH: Structure and function of telomeres. Nature 350: 569-573, 1991.
4. Greider CW: Chromosome first aid. Cell 67: 645-647, 1991.
5. Harley CB, Futcher AB and Greider CW: Telomeres shorten during ageing of human fibroblasts. Nature 345: 458-460, 1990. (Pubitemid 20178256)
6. Meyerson M, Counter CM, Eaton EN, et al: hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 90: 785-795, 1997. (Pubitemid 27357969)
7. Nakamura TM, Morin GB, Chapman KB, et al: Telomerase catalytic subunit homologs from fission yeast and human. Science 277: 955-959, 1997.
8. Weinrich SL, Pruzan R, Ma L, et al: Reconstitution of human telomerase with the template RNA component hTR and the catalytic protein subunit hTRT. Nat Genet 17: 498-502, 1997.
9. Bodnar AG, Ouellette M, Frolkis M, et al: Extension of lifespan by introduction of telomerase into normal human cells. Science 279: 349-352, 1998. (Pubitemid 28063364)
10. Kim NW, Piatyszek MA, Prowse KR, et al: Specific association of human telomerase activity with immortal cells and cancer. Science 266: 2011-2015, 1994.
11. Shay JW and Bacchetti S: A survey of telomerase activity in human cancer. Eur J Cancer 33: 787-791, 1997. (Pubitemid 27239490)
12. Lan KH, Kanai F, Shiratori Y, et al: In vivo selective gene expression and therapy mediated by adenoviral vectors for human carcinoembryonic antigen-producing gastric carcinoma. Cancer Res 57: 4279-4284, 1997.
13. Gu J, Kagawa S, Takakura M, Kyo S, Inoue M, Roth JA and Fang B: Tumor-specific transgene expression from the human telomerase reverse transcriptase promoter enables targeting of the therapeutic effects of the Bax gene to cancers. Cancer Res 60: 5359-5364, 2000.
14. Terazaki Y, Yano S, Yuge K, et al: An optimal therapeutic expression level is crucial for suicide gene therapy for hepatic metastatic cancer in mice. Hepatology 37: 155-163, 2003. (Pubitemid 36042156)
15. Koga S, Hirohata S, Kondo Y, et al: A novel telomerase-specific gene therapy: gene transfer of caspase-8 utilizing the human telomerase catalytic subunit gene promoter. Hum Gene Ther 11: 1397-1406, 2000. (Pubitemid 30451020)
16. Majumdar AS, Hughes DE, Lichtsteiner SP, Wang Z, Lebkowski JS and Vasserot AP: The telomerase reverse transcriptase promoter drives efficacious tumor suicide gene therapy while preventing hepatotoxicity encountered with constitutive promoters. Gene Ther 8: 568-578, 2001. (Pubitemid 32409532)
17. Irving J, Wang Z, Powell S, et al: Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity. Cancer Gene Ther 11: 174-185, 2004. (Pubitemid 38280520)
18. Zou W, Luo C, Zhang Z, et al: A novel oncolytic adenovirus targeting to telomerase activity in tumor cells with potent. Oncogene 23: 457-464, 2004. (Pubitemid 38175000)
19. Nagano S, Oshika H, Fujiwara H, Komiya S and Kosai K: An efficient construction of conditionally replicating adenoviruses that target tumor cells with multiple factors. Gene Ther 12: 1385-1393, 2005. (Pubitemid 43090388)
20. Kamizono J, Nagano S, Murofushi Y, Komiya S, Fujiwara H, Matsuishi T and Kosai K: Survivin-responsive conditionally replicating adenovirus exhibits cancer-specific and efficient viral replication. Cancer Res 65: 5284-5291, 2005.
21. Komata T, Koga S, Hirohata S, et al: A novel treatment of human malignant gliomas in vitro and in vivo: FADD gene transfer under the control of the human telomerase reverse transcriptase gene promoter. Int J Oncol 19: 1015-1020, 2001.
22. Jacob D, Davis J, Zhu H, et al: Suppressing orthotopic pancreatic tumor growth with a fiber-modified adenovector expressing the TRAIL gene from the human telomerase reverse transcriptase promoter. Clin Cancer Res 10: 3535-3541, 2004. (Pubitemid 38685464)
23. Broccoli D, Young JW and De Lange T: Telomerase activity in normal and malignant hematopoietic cells. Proc Natl Acad Sci USA 92: 9082-9086, 1995.
24. Kolquist KA, Ellisen LW, Counter CM, et al: Expression of TERT in early premalignant lesions and a subset of cells in normal tissues. Nat Genet 19: 182-186, 1998.
25. Kyo S, Takakura M, Kohama T and Inoue M: Telomerase activity in human endometrium. Cancer Res 57: 610-614, 1997.
26. Masutomi K, Yu EY, Khurts S, et al: Telomerase maintains telomere structure in normal human cells. Cell 114: 241-253, 2003. (Pubitemid 36936917)
27. Ikoma T, Takahashi T, Nagano S, et al: A definitive role of RhoC in metastasis of orthotopic lung cancer in mice. Clin Cancer Res 10: 1192-1200, 2004. (Pubitemid 38198921)
28. Kawai T, Takahashi T, Esaki M, Ushikoshi H, Nagano S, Fujiwara H and Kosai K: Efficient cardiomyogenic differentiation of embryonic stem cell by fibroblast growth factor 2 and bone morphogenetic protein 2. Circ J 68: 691-702, 2004. (Pubitemid 38906628)
29. Yan P, Coindre JM, Benhattar J, Bosman FT and Guillou L: Telomerase activity and human telomerase reverse transcriptase mRNA expression in soft tissue tumors: correlation with grade, histology and proliferative activity. Cancer Res 59: 3166-3170, 1999. (Pubitemid 29316017)
30. Zhu X, Kumar R, Mandal M, et al: Cell cycle-dependent modulation of telomerase activity in tumor cells. Proc Natl Acad Sci USA 93: 6091-6095, 1996. (Pubitemid 26190808)
31. Takakura M, Kyo S, Kanaya T, Hirano H, Takeda J, Yutsudo M and Inoue M: Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells. Cancer Res 59: 551-557, 1999. (Pubitemid 29076049)
32. Ushikoshi H, Takahashi T, Chen X, et al: Local overexpression of HB-EGF exacerbates remodeling following myocardial infarction by activating noncardiomyocytes. Lab Invest 85: 862-873, 2005.
33. Nagano S, Yuge K, Fukunaga M, Terazaki Y, Fujiwara H, Komiya S and Kosai K: Gene therapy eradicating distant disseminated micro-metastases by optimal cytokine expression in the primary lesion only: novel concepts for successful cytokine gene therapy. Int J Oncol 24: 549-558, 2004.
34. Yuge K, Takahashi T, Nagano S, et al: Adenoviral gene transduction of hepatocyte growth factor elicits inhibitory effects for hepatoma. Int J Oncol 27: 77-85, 2005.
35. Scheel C, Schaefer KL, Jauch A, et al: Alternative lengthening of telomeres is associated with chromosomal instability in osteosarcomas. Oncogene 20: 3835-3844, 2001. (Pubitemid 32646194)
36. Gan Y, Mo Y, Johnston J, Lu J, Wientjes MG and Au JL: Telomere maintenance in telomerase-positive human ovarian SKOV-3 cells cannot be retarded by complete inhibition of telomerase. FEBS Lett 527: 10-14, 2002. (Pubitemid 35253830)
37. Nakayama J, Tahara H, Tahara E, et al: Telomerase activation by hTRT in human normal fibroblasts and hepatocellular carcinomas. Nat Genet 18: 65-68, 1998. (Pubitemid 28027882)
38. Tomlinson RL, Ziegler TD, Supakorndej T, Terns RM and Terns MP: Cell cycle-regulated trafficking of human telomerase to telomeres. Mol Biol Cell 17: 955-965, 2006. (Pubitemid 43191127)
39. Chu RL, Post DE, Khuri FR and Van Meir EG: Use of replicating oncolytic adenoviruses in combination therapy for cancer. Clin Cancer Res 10: 5299-5312, 2004.
40. Ido A, Nakata K, Kato Y, et al: Gene therapy for hepatoma cells using a retrovirus vector carrying herpes simplex virus thymidine kinase gene under the control of human alpha-fetoprotein gene promoter. Cancer Res 55: 3105-3109, 1995.
41. Tanaka T, Kanai F, Okabe S, et al: Adenovirus-mediated prodrug gene therapy for carcinoembryonic antigen-producing human gastric carcinoma cells in vitro. Cancer Res 56: 1341-1345, 1996. (Pubitemid 26080977)
42. Fukunaga M, Takamori S, Hayashi A, Shirouzu K and Kosai K: Adenoviral herpes simplex virus thymidine kinase gene therapy in an orthotopic lung cancer model. Ann Thorac Surg 73: 1740-1746, 2002. (Pubitemid 34596710)
43. Lanson NA Jr, Friedlander PL, Schwarzenberger P, Kolls JK and Wang G: Replication of an adenoviral vector controlled by the human telomerase reverse transcriptase promoter causes tumor-selective tumor lysis. Cancer Res 63: 7936-7941, 2003. (Pubitemid 37466730)
44. Painter RG, Lanson NA Jr, Jin Z, Park F and Wang G: Conditional expression of a suicide gene by the telomere reverse transcriptase promoter for potential post-therapeutic deletion of tumorigenesis. Cancer Sci 96: 607-613, 2005. (Pubitemid 41488424)
45. Fujimoto K, Kyo S, Takakura M, et al: Identification and characterization of negative regulatory elements of the human telomerase catalytic subunit (hTERT) gene promoter: possible role of MZF-2 in transcriptional repression of hTERT. Nucleic Acids Res 28: 2557-2562, 2000.